Grade and Stage

What the cells look like: grade

Grade is a property of the tumour itself — an assessment of how abnormal the cancer cells appear under the microscope and how rapidly they seem to be dividing. The system most widely used today is the Nottingham Grading System, developed by Christopher Elston and Ian Ellis and published in 1991 as a refinement of an earlier scheme by Scarff, Bloom and Richardson. Three features are scored individually: how much the cells still attempt to form tubular structures (tubule formation), how irregular the nuclei look (nuclear pleomorphism), and how many dividing cells can be counted in a standard field (mitotic count). Each receives a score of one to three, and the totals are summed.

A combined score of three to five is Grade 1 — cells that still resemble normal breast tissue and divide slowly. Six or seven is Grade 2, an intermediate appearance. Eight or nine is Grade 3: cells that look markedly abnormal and proliferate quickly. Grade is therefore a statement about biology — about how much the tumour has drifted from its tissue of origin. It says nothing, on its own, about where in the body that tumour is located or whether it has moved anywhere.

Where the disease has gone: stage

Stage answers a different question entirely. It describes the anatomical extent of disease at the time of diagnosis: the size of the primary tumour, whether regional lymph nodes are involved, and whether there is spread to distant sites. The dominant framework is the TNM classification, maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). T is tumour size, N is nodal status, M is metastasis. Combining those three dimensions produces an overall stage from I to IV.

Stage I is a small tumour confined to the breast. Stage II tumours are larger or have spread to a limited number of nearby axillary lymph nodes. Stage III — locally advanced disease — involves more extensive nodal involvement or direct spread into the chest wall or skin. Stage IV means the disease has reached distant organs: lung, liver, bone or brain are the commonest sites. Unlike grade, stage is dynamic in the sense that it is reassessed over time: although it is recorded at a fixed point, re-staging occurs if disease progresses or recurs.

The AJCC's eighth edition, published in 2017, added biomarkers — oestrogen receptor status, HER2 status and multigene panel scores — into staging for the first time, producing what it calls prognostic stage groups alongside the anatomical ones. This acknowledged what decades of trial data had already made clear: two tumours with identical size and nodal status can behave very differently depending on their molecular profile.

Why the distinction matters

The two measures move independently and capture different aspects of the disease. A grade 3 tumour can be diagnosed at stage I if it is small and has not spread — aggressive biology, caught early. A grade 1 tumour presenting with extensive nodal involvement is stage III — indolent cells, advanced anatomical extent. Neither number predicts outcome in isolation. Oncologists, pathologists and trialists use both together because each adds information the other does not carry.

The separation also clarifies what different treatments are targeting. Systemic therapies — chemotherapy, hormonal agents, targeted drugs — are chosen partly on grade and molecular markers because those reflect the tumour's biological behaviour. Decisions about surgery and radiotherapy are shaped more by stage, because those treatments address the local and regional extent of disease. The Early Breast Cancer Trialists' Collaborative Group, which pools individual patient data from randomised trials, has consistently needed both variables when modelling outcomes across thousands of participants, because omitting either one leaves meaningful variation unexplained.

Confusing grade with stage — treating them as synonyms for "how bad" — collapses a distinction that the last four decades of evidence have worked hard to make precise.